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A B S T R A C T
The fungal pathogen Cryptococcus neoformans poses a major threat to immunocompromised patients and
is a leading killer of human immunodeﬁciency virus (HIV)-infected patients worldwide. Cryptococci are
known to manipulate host macrophages and can either remain latent or proliferate intracellularly within
the host phagocyte, a favourable niche that also renders them relatively insensitive to antifungal agents.
Here we report an attempt to address this limitation by using a ﬂuorescence-based drug screening method
to identify potential inhibitors of intracellular proliferation of C. neoformans. The Prestwick Chemical Library®
of FDA-approved small molecules was screened for compounds that limit the intracellular replication
of a ﬂuorescently-tagged C. neoformans reference strain (H99-GFP) in macrophages. Preliminary screen-
ing revealed 19 of 1200 compounds that could signiﬁcantly reduce intracellular growth of the pathogen.
Secondary screening and host cell cytotoxicity assays highlighted fendiline hydrochloride as a potential
drug candidate for the development of future anticryptococcal therapies. Live cell imaging demon-
strated that this Ca2+ channel blocker strongly enhanced phagosome maturation in macrophages leading
to improved fungal killing and reduced intracellular replication. Whilst the relatively high dose of fendiline
hydrochloride required renders it unﬁt for clinical deployment against cryptococcosis, this study high-
lights a novel approach for identifying new lead compounds and unravels a pharmacologically promising
scaffold towards the development of novel antifungal therapies for this neglected disease.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Cryptococcus neoformans is an opportunistic fungal pathogen that
can cause fatal infections in immunocompromised individuals. The
infection process begins with inhalation of infectious agents (spores
or desiccated yeasts) resulting in a primary pulmonary infection,
which, in response to immunosuppression, can further dissemi-
nate to the central nervous system causing meningitis [1]. Human
immunodeﬁciency virus/acquired immune deﬁciency syndrome
(HIV/AIDS) patients are particularly prone to cryptococcal infec-
tions, with an estimated overwhelming disease burden of
approximately one million cases of cryptococcal meningitis (CM)
per year [2,3]. The highest incidence of CM-related deaths in HIV-
positive patients occurs in sub-Saharan Africa, with an associated
mortality of 70% [2]. Despite the advent of highly active antiretroviral
therapy, CM-related mortality remains prevalent among HIV/AIDS
patients in developing regions [4,5].
Alveolar macrophages form the ﬁrst line of defence against Cryp-
tococcus, however the fungus is able to survive and replicate within
the macrophage phagosome following internalisation [6–8]. The
exact mechanisms facilitating intracellular survival of the patho-
gen within phagosomes are not fully understood, but recent data
suggest that the process of phagosomal maturation is subtly per-
turbed leading to reduced antimicrobial activity in this compartment
[9] and phagolysosomal damage [10]. Continued replication of the
fungus eventually leads to lysis of the host macrophage or non-
lytic release of the pathogen by a process termed vomocytosis [11,12].
Current World Health Organization (WHO) guidelines for CM
management in AIDS patients recommend ‘gold-standard’ combi-
nation therapy with amphotericin B (AmB) and 5-ﬂucytosine (5-
FC) followed by lifelongmaintenance with ﬂuconazole (FLU) [13,14].
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However, the need for intravenous dosing together with
signiﬁcant clinical toxicity and thus a requirement for therapeutic
monitoring, particularly for optimising 5-FC dosing in patients with
renal impairment, has limited deployment of this approach in
resource-limited settings [15–17]. Therefore, novel and effective al-
ternatives to these mainstay anticryptococcal drugs are needed.
Compounds that drive clearance of cryptococci from the intracel-
lular niche offer a powerful alternative approach to treating
cryptococcosis and may hold promise as adjunct therapy to use
alongside existing antifungals.
To identify such compounds, we have employed a high-
throughput ﬂuorescence-based screening approach to probe 1200
US Food and Drug Administration (FDA)-approved small mol-
ecules for their ability to inhibit intracellular proliferation of
C. neoformans in murine macrophages (Fig. 1). Shortlisted com-
pounds were further probed for host cell cytotoxicity and antifungal
activity, and lead molecules were validated in vitro by intracellu-
lar killing assays, leading to the identiﬁcation of fendiline
hydrochloride as a potential candidate compound. Finally, we dem-
onstrated that fendiline hydrochloride improves the phagosomal
maturation rate and thus facilitates killing of C. neoformans within
the host cell.
2. Materials and methods
2.1. Yeast cells and growth conditions
All reagents were purchased from Sigma unless otherwise stated.
Green ﬂuorescence protein (GFP)-expressing C. neoformans sero-
type A strain (H99-GFP) and Cryptococcus gattii serotype B strain
(R265-GFP) were used for this study [18] and were grown over-
night in YPDmedium (2% glucose, 1% peptone and 1% yeast extract)
on a rotator revolving at 240 rpm at 25 °C prior to all experiments.
2.2. Macrophage cell line culture
Cells from the murine macrophage-like cell line J774A.1 were
used between passages 4 and 14 after thawing and were cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
2mM l-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin and
10% foetal bovine serum (FBS) at 37 °C and 5% CO2.
2.3. Assay development and primary screening assay
The Prestwick Chemical Library® containing approximately 1200
FDA-approved small molecules was accessed via the Birmingham
Drug Discovery Facility (University of Birmingham, Birmingham, UK).
Shortlisted compounds were repurchased from Sigma-Aldrich unless
otherwise mentioned. The drugs were dissolved in dimethyl
sulphoxide (DMSO), which served as a negative control, and were
used at a ﬁnal assay concentration of 10 μM, and AmB (ﬁnal assay
concentration 1.25 μg/mL) was used as a positive control. Primary
screening of compounds was performed at the Drug Discovery Unit
(University of Birmingham) using a Hamilton STAR liquid han-
dling robot (Hamilton Robotics, Bonaduz, Switzerland) integrated
with a microplate reader (BMG LABTECH, Ortenberg, Germany) en-
abling GFP ﬂuorescencemeasurement. Macrophages (0.25 × 105 cells/
well) were seeded in a glass-bottom 96-well plate (Greiner Bio One
Ltd., Stonehouse, UK) 18 h before infection. An overnight culture of
strain H99-GFP was harvested by centrifugation at 6500 rpm for
2.5 min, washed three times with phosphate-buffered saline (PBS)
and opsonised with 5% pooled human serum (not heat-inactivated)
for 1 h at room temperature prior to infection. Macrophages were
activated with 150 ng/mL phorbol myristate acetate (PMA) for 1 h
in DMEM without FBS and were infected with yeast cells [multi-
plicity of infection (MOI) 10:1] for 2 h at 37 °C. At this point, total
GFP ﬂuorescence was measured (t0′) to control for well-to-well vari-
ation in cryptococcal exposure. Then, themediumwas aspirated and
cells were washed with PBS to remove extracellular yeasts. The GFP
ﬂuorescence corresponding to only intracellular yeast was mea-
sured (t0) and medium containing drugs was added to the cells and
was incubated for a further 18 h at 37 °C in 5% CO2. After 18 h, the
GFP ﬂuorescence was measured (t18′) to determine the total yeast
burden. Extracellular yeast was then removed by washing with PBS
and a ﬁnal GFP ﬂuorescence reading (representing intracellular yeast
only) was taken (t18). The total (intracellular plus extracellular) pro-
liferation rate (PR) was quantiﬁed as the relative ﬂuorescence ratio
of t18′/t0′, whilst the intracellular proliferation rate (IPR) was quan-
tiﬁed as the ratio t18/t0. The statistical parameters signal-to-basal
(S/B) ratio, Z′ factor and percent coeﬃcient of variation (%CV) were
calculated as follows [19]:
′ = − +( ) −Z n p n p1 3 3σ σ μ μ
S B n p= μ μ
% CV n n= ×σ μ 100
where μn, σn, μp and σp are the means (μ) and standard deviations
(σ) of the negative and positive controls, respectively.
2.4. Secondary screening (phagosomal maturation studies)
Macrophages (0.5 × 105 cells/well) were seeded into a glass-
bottom 96-well plate and were infected with serum-opsonised H99-
GFP cells (MOI 10:1) following activation with PMA as described
above. Where necessary, yeasts were heat-killed at 55–60 °C for
30 min before serum opsonisation and infection as described pre-
viously [9]. At 2 h post-infection, mediumwas replaced with serum-
free DMEM supplemented with 5 μM of drugs (equivalent to 0.1%
DMSO) or 1.25 μg/mL AmB containing the acidotropic dye 50 nM
LysoTracker® Red DND-99 (Invitrogen, Molecular Probes, Waltham,
MA). Cells were then taken for live imaging for 18 h.
Fig. 1. Screening strategy for library molecules. A total of 1200 US Food and Drug
administration (FDA)-approved small molecules were screened for intracellular growth
inhibition of Cryptococcus neoformans in macrophages. The primary screen yielded
19 active compounds that were further probed for host cell cytotoxicity and fungal
growth inhibition. Eleven compounds were shortlisted for phagosomal maturation
screening, which identiﬁed only one promising drug hit candidate, D9 (fendiline hy-
drochloride). Finally, the mechanism of action of fendiline was investigated. MoA,
mode of action.
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2.5. Cytotoxicity assay
Macrophage cell cytotoxicity of the compounds was tested using
the LDH Cytotoxicity Detection Kit (Takara Bio Inc., Kusatsu, Japan)
according to the manufacturer’s protocol. Macrophages were seeded
into 96-well plates at a density of either 0.25 × 105 cells/well or
0.5 × 105 cells/well and were cultured overnight. Medium was re-
placed with serum-free DMEM containing either 5 μM or 10 μM of
drug and cells were incubated at 37 °C in 5% CO2 for a further 18 h.
Lactate dehydrogenase (LDH) enzyme released into the cell culture
supernatant was measured as a colorimetric change after addition
of reaction mixture. The plate was read at 490 nm using a FLUOstar
Omega Microplate Reader (BMG Labtech) after 10 min incubation
at room temperature. 1% Triton X-100 was used as a positive control.
Treatments were done in triplicate and the mean absorbance was
calculated. The percent cytotoxicity for samples was expressed as
a percentage of the positive control (100% for positive control).
2.6. Live imaging
Time-lapse imagingwas performed at 37 °C using a Nikon TE2000
microscope (Nikon, Tokyo, Japan) in a humidiﬁed chamber with 5%
CO2 with a 20× or 60× objective (Nikon) as indicated. Images were
captured every 5 min for 18 h and were analysed using NIS-
Elements Advanced Research software (Nikon). The IPR was
determined at 12 h (t12) due to excessive extracellular cryptococ-
cal growth at 18 h precluding measurement at this time point.
2.7. Fungal growth inhibition assay
For the fungal growth inhibition assay, 105 yeast cells were added
per well in YPD broth supplemented with 5 μM of drug or the re-
spective control (1.25 μg/mL AmB or 0.1% DMSO) in a 48-well plate
(Greiner Bio One). Fungal growth kinetics was measured over a 24-h
time period by reading the plate at 600 nm every 30 min using a
FLUOstar OmegaMicroplate Reader. Plates were incubated through-
out at 25 °C in the plate reader.
2.8. Statistical analysis
All statistical analyseswere performed using GraphPad Prism soft-
ware (GraphPad Software Inc., La Jolla, CA) with all data represented
as the mean ± standard deviation (S.D.) from at least three inde-
pendent experiments unless otherwise stated. Data analyses were
done using the Mann–Whitney U-test, one-way analysis of vari-
ance (ANOVA) or Fisher’s exact test (two-tailed) as indicated in the
respective ﬁgure legends.
3. Results
3.1. Assay development to monitor intracellular proliferation of
C. neoformans in macrophages and primary screen design
To identify small molecules that inhibit the intracellular growth
of C. neoformans in macrophages, a high-throughput ﬂuorescence-
based automated screen was designed to score replication of a GFP-
expressing C. neoformans in macrophages (Fig. 1). Macrophages were
infected with strain H99-GFP in 96-well plates and the IPR of the
yeast was quantiﬁed by GFP ﬂuorescence after 18 h following phago-
cytosis and drug addition. As a proof of concept and in order to
establish the accuracy of the assay principle in evaluating intracel-
lular proliferation of H99-GFP under different drug treatments, the
IPR and total PR in response to DMSO, AmB and FLU were ﬁrst as-
sessed manually (Fig. 2A). Whilst the IPR values remained mostly
consistent for DMSO (the carrier control) and FLU (which has poor
penetration into the phagosome), it decreased signiﬁcantly for AmB
(Fig. 2A), demonstrating that the screening set-up is able to dis-
criminate agents that are active intracellularly from those with only
extracellular activity. Therefore, we proceeded with the high-
throughput screen using DMSO and AmB as negative and positive
controls, respectively, which yielded signiﬁcantly different IPR values
for DMSO and AmB treatments (Fig. 2B). High-throughput screens
are typically characterised by a Z′ factor ≥0.5 and high S/B values
[19,20]. According to Zhang et al, an assay with a Z′ value >0 and
<0.5 is considered to bemarginal but feasible for screening [19]. Both
the Z′ factor (0.37) and S/B (4.3) values for our screen fell within
the range that is deemed suitable for high-throughput screening
[19,20], and the %CV value of 12% was well below the recom-
mended 20% limit [20] (Table 1; Fig. 2B). Thus, the screening
procedure, whilst inherently noisy, appears suﬃciently sensitive to
identify promising lead compounds.
To exclude the possibility of molecules inhibiting phagocytic
uptake of yeasts, the compound library was added after phagocy-
tosis. From the preliminary screening, only those compounds that
exhibited a statistically signiﬁcant decrease in IPR (i.e. 2 S.D. lower
than the mean IPR of the total 1200 compounds) were considered
as ‘primary hits’ (Fig. 2C). This preliminary screening yielded a total
of 19 small molecules that signiﬁcantly inhibited intracellular growth
relative to the DMSO control (data not shown). Compounds that vi-
sually exhibited signiﬁcant macrophage toxicity or with previously
reported antimicrobial (including antifungal) activity were further
discarded. Compounds that signiﬁcantly lowered PR values (i.e.
showed potent extracellular fungicidal effects) were also excluded
(data not shown). After applying these ﬁlters, 13 unique mol-
ecules that limit C. neoformans survival in macrophages were
identiﬁed. These selected compounds were repurchased from com-
mercial sources for further tests and are denoted as D2–D14 (data
not shown).
3.2. Validating host cell cytotoxicity and direct antifungal activity of
D2–D14 compounds
To conﬁrm the primary screen-speciﬁc effects, the 13 selected
repurchased compoundswere tested under different conditions using
a reduced compound concentration (5 μM), lower DMSO content
(0.1%) and higher macrophage density. As observed in Fig. 3A, treat-
ment of amacrophage cell density of 0.25 × 105 cells/well with 10 μM
compounds (1.25 μg/mL AmB) and a corresponding 2.5% DMSO
control yielded a high level of macrophage cytotoxicity. In con-
trast, treatment with a 5 μM drug dose corresponding to a lowDMSO
content of 0.1% and higher cell density (0.5 × 105 cells/well) en-
hanced macrophage survival (Fig. 3B), thereby prompting us to use
the latter setting for further investigation.
We validated that the selected doses of the compounds (5 μM
and corresponding 0.1% DMSO) were not directly toxic to the fungi.
For this, the growth inhibitory activity of the selected compounds
was tested against an H99-GFP axenic culture over a period of 24 h
(Fig. 3C). Compounds D5 and D6 signiﬁcantly inhibited fungal growth
to the same extent as the positive control AmB and were there-
fore excluded from further screening. The remainder of the
compounds exhibited comparable growth kinetics to the un-
treated control, suggesting that these compounds do not exhibit
Table 1
Summary of quality control parameters for screening assay (n = 100).
Statistical parameter Value
Z′ factor 0.37
S/B ratio 4.3
%CV 12.01
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direct antifungal activity but rather suppress intracellular growth
of the fungus (Fig. 3C).
3.3. Secondary screening reveals D9-triggered phagosomal
acidiﬁcation in macrophages
To probe how the remaining 11 compounds reduced the intra-
cellular proliferation of C. neoformans, their effect on phagosome
maturation was assessed. Phagosome maturation is a multistep
process eventually resulting in phagolysosome fusion, acidiﬁca-
tion and enhanced antimicrobial properties [21]. Several intracellular
pathogens such asMycobacterium tuberculosis, Legionella pneumophila,
Salmonella Typhimurium and Leishmania donovani evade macro-
phage killing by perturbing the phagosomal maturation process
[22,23]. Recently, we showed that C. neoformans is also capable of
altering phagosomal acidiﬁcation in host cells to facilitate intra-
cellular survival [9]. Therefore, we considered the possibility that
compounds identiﬁed as reducing intracellular growth of crypto-
cocci may do so by improving phagosomal maturation. To test this
hypothesis, phagosome acidiﬁcation was monitored using the ﬂu-
Fig. 2. Assay development and determination of Z′ factor for automated screen. (A) Manual intracellular proliferation rate (IPR) evaluation for different drug treatments,
including 2% dimethyl sulphoxide (DMSO), 1.25 μg/mL amphotericin B (AmB) and 10 μg/mL ﬂuconazole (FLU). Values represent the mean ± standard deviation (S.D.) from
four independent experiments [IPR and proliferation rate (PR) separately analysed by Mann–Whitney U-test, *P < 0.05]. (B) Scatter plot showing the distribution of DMSO-
treated (negative control) and AmB-treated (positive control) signal representing the IPR of H99-GFP in macrophages (n = 100). (C) Primary screening of 1200 Prestwick
Chemical Library® compounds using automatic robot showing the mean IPR of all compounds (solid black line) as well as two S.D. higher and lower IPR values (dashed
black lines). IPR value of AmB is indicated in red. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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orescent acidotropic dye LysoTracker Red in response to drug
treatment during infection. Whilst live untreated cryptococci-
containing phagosomes hardly acquired a LysoTracker-positive signal,
almost 100% of the phagosomes in the heat-killed control became
LysoTracker-positive over the 18 h period of infection (Fig. 4A). Most
of the drug treatments, including the DMSO control, did not yield
any signiﬁcant phagosomal acidiﬁcation compared with the un-
treated control (Fig. 4A). Interestingly, however, treatment with drug
D9 signiﬁcantly enhanced phagosomal acidiﬁcation and yielded a
striking 87.14% LysoTracker-positive phagosomes compared with
untreated and DMSO controls (Fig. 4A–D; Supplementary
Movies S1–S3). Surprisingly, D9 yielded signiﬁcantly higher
Fig. 3. Effect of drug treatments on host cell cytotoxicity and fungal growth inhibition. (A,B) Lactate dehydrogenase (LDH) released from murine macrophages was mea-
sured after 18 h of drug treatment with 10 μM drugs (2.5% DMSO) (A) and 5 μM drugs (0.1% DMSO) (B), and 1.25 μg/mL AmB. 0.1% Triton X-100 was used as a positive control.
Values represent the mean ± standard deviation (S.D.) from three independent experiments (one-way ANOVA + Dunnett’s post-test, *P < 0.05, **P < 0.01 and ***P < 0.001).
(C) Effect of 5 μΜ drugs (0.1% DMSO) on growth kinetics of H99-GFP cells. AmB (1.25 μg/mL) was used as a positive control. The growth curve shown is representative of
three independent experiments. Values represent mean ± S.D. DMSO, dimethyl sulphoxide; NT, untreated cells.
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LysoTracker-positive signal than AmB, which is a mainstay
anticryptococcal drug with fungicidal activity against cryptococci
but generated only 43.53% LysoTracker-positive phagosomes up to
18 h of infection (Fig. 4A; Supplementary Movie S1). Upon careful
analysis of time-lapsemovies, it was found that the D9-induced acid-
iﬁcation events occurred typically within the ﬁrst 4–5 h of infection
(Fig. 4D; SupplementaryMovie S3). Conversely, untreated and DMSO-
treated phagosomes remained mostly negative at that time point
(Fig. 4B,C; Supplementary Movies S2 and S3) and failed to retain a
signiﬁcant amount of LysoTracker-positive signal even 18 h post-
infection. Thus, D9 appears to act by enhancing phagosomal
maturation and either killing or disabling the intracellular
cryptococci.
3.4. Drug D9 is active against intracellular cryptococci at 5 μM but
loses eﬃcacy at 1 μM
Next, we were prompted to analyse the eﬃcacy of D9 at a lower
dose of 1 μM that would be ideal for clinical applications. However,
D9 failed to retain its activity upon lowering the drug dose and the
LysoTracker-positive signal signiﬁcantly dropped to 3.58% com-
pared with that of the 5 μM dose (Fig. 5A). Furthermore, the effect
of D9 at both doses on intracellular proliferation of C. neoformans
in macrophages was assessed from time-lapsemovies until 12 h post
infection (Fig. 5B). Congruently with its effect on phagosomal acid-
iﬁcation, a 5 μM dose of D9 signiﬁcantly reduced the IPR of H99-
GFP cells in macrophages compared with untreated and DMSO
Fig. 4. Effect of drugs on macrophage phagosomal maturation. (A) Phagosomal acidiﬁcation was quantiﬁed by staining with LysoTracker® Red and is indicated by percent
LysoTracker-positive cryptococcal-containing phagosomes (CCPs) after 18 h treatment with 5 μM drugs. Heat-killed cells served as a positive control. Values represent the
mean ± standard deviation (S.D.) collected from observing 300–400 phagosomes at each time point for each treatment across three to ﬁve biological repeats (Fisher’s exact
test, ***P < 0.001; NS, not signiﬁcant). (B–D) Merged images of brightﬁeld, green ﬂuorescent protein (GFP) and LysoTracker Red (red ﬂuorescence) taken from time-lapse
microscopy experiments at the indicated time points post-phagocytosis on a 60× objective. Images from panels B, C and D represent status of phagosomal acidiﬁcation by
accumulation of LysoTracker Red in CCPs for untreated (NT), DMSO control and D9-treated cells, respectively. Phagocytosed cryptococci are indicated by arrowheads (white).
Time-lapse frames are extracted from Supplementary Movies S1–S3.
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controls. Conversely, D9 failed to inhibit intracellular growth of Cryp-
tococcus at the lower dose of 1 μM and retained an IPR level
comparable with the untreated control, suggesting loss of eﬃcacy
at this dose (Fig. 5B). This strong threshold effect itself reﬂects a re-
quirement for a minimum signalling ﬂux to activate the phagosome
maturation pathway in order to successfully kill intracellular
cryptococci.
To test whether the activity of D9 is species-speciﬁc, the effect
of D9 on phagosomal acidiﬁcation against the other main patho-
genic cryptococcal species, C. gattii (R265-GFP), was also tested. As
with C. neoformans, D9 effectively increased LysoTracker-positivity
of C. gattii phagosomes, an effect that dropped signiﬁcantly with
reduced drug dosage (Supplementary Fig. S1), suggesting that this
drug is effective against both human-infective species of Cryptococcus.
Unblinding the screening compounds revealed D9 to be fendiline
hydrochloride, a known inhibitor of l-type Ca2+ channels that re-
portedly increases the intracellular Ca2+ concentration [Ca2+]i via
calcium release from endoplasmic reticulum stores [24,25]. There-
fore, to assess the intracellular calcium ﬂux in macrophages in
response to fendiline, drug concentrations ranging from 1 to 20 μM
were tested to check the concentration-dependent effects previ-
ously reported for other cell types with this drug [24–26] (see
Supplementary method). Interestingly, fendiline barely had an effect
on [Ca2+]i at a concentration of 1 μM compared with the DMSO
control (Supplementary Fig. S2A), but the [Ca2+]i markedly in-
creased at 5 μM or 20 μM (Supplementary Fig. S2A). Thus, this sharp
concentration threshold is likely attributable to the differential ef-
ﬁcacy observed between 1 μM and 5 μM. Furthermore, to investigate
whether the rise in [Ca2+]i upon fendiline treatment is mainly due
to discharge of Ca2+ from intracellular stores, we tested whether the
inhibitor thapsigargin speciﬁcally blocking endoplasmic reticu-
lum Ca2+ pumps could alleviate the rise in [Ca2+]i observed with
fendiline [25,26] (see Supplementary method). Indeed, exposing the
cells to 0.5 μM thapsigargin caused a signiﬁcant drop in [Ca2+]i com-
pared with the cells exposed to only 5 μM fendiline (Supplementary
Fig. S2B). These results suggest that fendiline induces a Ca2+ sig-
nalling ﬂux in J774A.1 macrophages that involves Ca2+ inﬂux to the
cytoplasm from intracellular stores.
4. Discussion
Considering the poor status of current anticryptococcal drugs,
new treatment options for cryptococcosis are much needed. Studies
from several groups have attempted to address this and have mostly
focused on drugs that act on extracellular, rather than intracellu-
lar, cryptococci [27,28]. Recently, Butts et al screened the Prestwick
library of FDA-approvedmolecules to identify compoundswith direct
fungicidal activity against C. neoformans based on loss of cellular in-
tegrity and thereby release of intracellular enzyme adenylate kinase
[16]. Although our screening assay utilised the same compound
library, it is complementary in approach since it was designed to
identify only those molecules that induce intracellular killing, ex-
cluding all molecules with direct antifungal activity (including those
identiﬁed by Butts et al). Importantly, there are no previously re-
ported screens designed to identify adjunct therapies that may
augment macrophage-based killing of cryptococci. Therefore, we de-
veloped a simple approach to screen the Prestwick compound library
by infecting macrophages with the H99-GFP strain and quantify-
ing the GFP ﬂuorescence as an index for intracellular proliferation.
Similar approaches to probe intracellular replication using GFP ex-
pression have been successfully applied for other intracellular
pathogens such as M. tuberculosis [29] and Leishmania [30]. Intra-
cellular screens are technically challenging, as reﬂected by the
relatively poor Z′ score and S/B ratio of our screen, and thus carry
a high false-negative rate. However, our screen was supported by
a valid %CV value and the fact that it identiﬁed the current
Fig. 5. Dose-dependent effect of D9 on phagosomal maturation and intracellular
killing. (A) Phagosomal acidiﬁcation at differential doses of D9 quantiﬁed by
LysoTracker® Red staining after treatment with the respective drug dose for 18 h.
Values represent the mean ± standard deviation (S.D.) collected from observing 300–
400 phagosomes at each time point for each treatment across three to ﬁve biological
repeats (Fisher’s exact test, ***P < 0.001). (B) Effect of respective doses of D9 on in-
tracellular viability of H99-GFP in J774A.1 murine macrophages as quantiﬁed from
time-lapse movies. The intracellular proliferation rate is calculated as t12/t0 ratio,
where t12 and t0 indicate the number of internalised cryptococci at 12 h and 0 h post-
infection, respectively; n = 3 (one-way ANOVA + Tukey post-test, ***P < 0.001; NS, not
signiﬁcant). NT, untreated; DMSO, dimethyl sulphoxide; AmB, amphotericin B; CCP,
cryptococcal-containing phagosome.
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frontline anticryptococcal drug (AmB) included in the library.
However, we note that there is a possibility that additional
anticryptococcal compounds within the collection may have been
missed by our screening strategy. Nonetheless, the screen suc-
ceeded in identifying a small set of lead compounds, at least one
of which appears to be a potential drug candidate.
The screening identiﬁed a novel compound D9 (fendiline hy-
drochloride), an l-type calcium-channel blocker widely used in the
treatment of angina [25,31]. Notably, D9 does not exhibit a direct
antifungal effect against C. neoformans, but instead triggers signif-
icant phagosomal acidiﬁcation in host macrophages. Fendiline is
thought to act by transiently elevating [Ca2+]i in certain cell types
via release from intracellular endoplasmic reticulum calcium stores
[25,26]. In agreement, we observed an increase in [Ca2+]i levels at
doses of fendiline above 5 μM, which is inhibited by blocking calcium
release from the endoplasmic reticulum with thapsigargin. Inter-
estingly, a previous study by Huang et al showed that a 1 μM dose
of fendiline barely triggered any signiﬁcant increase in [Ca2+]i above
baseline [25]. This may explain the strong threshold effect at 5 μM,
but almost none at the 1 μM drug dose. Considering that intracel-
lular calcium dynamics are altered during cryptococcal infection [9],
it is tempting to speculate that fendiline may re-adjust intracellu-
lar calcium signalling to allow full phagosome maturation and thus
fungal killing, a hypothesis that would be worthy of future inves-
tigation in appropriate animal models.
Pharmacologically, fendiline offers some attractive properties rel-
evant for C. neoformans infection. Its physiochemical structure
comprises a highly lipophilic region linked to a weak base, which
enables accumulation in intracellular acidic compartments such as
the phagolysosome [32,33]. In addition, it is known to be an FDA-
approved neuroprotective drug and is included in the
Neurodegeneration Drug Screening Consortium of 1040 com-
pounds, most of which have access to the blood–brain barrier [34].
This makes the drug scaffold relevant for the treatment of CM in-
fections [35]. However, fendiline itself appears only to be active in
vitro at concentrations signiﬁcantly higher than the typical serum
level of 0.6 μM following oral administration [36]. Although this
makes fendiline itself unﬁt for clinical translation, the drug scaf-
fold still offers scope for potential optimisation in the future to
improve either eﬃcacy or bioavailability. Alternatively, existing FDA-
approved compounds with structural similarity to fendiline may
provide promising lines of investigation that would not necessi-
tate extensive pre-clinical testing prior to clinical trials. Importantly,
previous studies have highlighted a role for calcium-channel block-
ers in inhibition of drug eﬄux pumps and drug resistance in
M. tuberculosis infection, which shares a similar intraphagosomal life-
style [37,38], and thus it is possible that fendiline-derived compounds
may have wide applicability.
In conclusion, this work demonstrates an effective screening plat-
form using a whole-cell-based approach to identify inhibitors against
intracellular proliferation of C. neoformans that can be potentially
applied to other intracellular pathogens. We identiﬁed a novel off-
patent drug, fendiline hydrochloride, that itself is not fungicidal to
C. neoformans but potently manipulates intraphagosomal replica-
tion and viability within the cell. Taken together, these ﬁndings
propose a role for calcium-channel blockers as potential inhibi-
tors of intracellular survival of C. neoformans in infectedmacrophages
and therefore represent a promising strategy for future
anticryptococcal drug design and therapy.
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